Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Iran war drives global fertilizer prices up, raising food cost fears - 2Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- 3Vote In favor of Your Favored Kind Of Bites
- 4How we came to be: Scientists get first look at the evolution of early complex animals
- 5Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- 7 Popular Vacation destinations In China
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- Revvity says it will exceed 2025 profit forecast range
- French Senate debates social media ban for under-15s
- Spots to Go Hang Floating
- Ukraine's new defense minister just outlined how dire its troop shortage has become
